Comorbidities Drive Outcomes for Both Malignancy-Associated and Non-Malignancy-Associated Hemophagocytic Syndrome

摘要

Secondary hemophagocytic syndrome (SHPS) is a rare syndrome that develops in the context of infection, autoimmune disease, or underlying malignancy, resulting in unregulated activation of the immune system. Through a retrospective analysis of a large inpatient national database and the Charlson comorbidity index (CCI), we identified novel predictors of mortality among 276 hospitalizations in adults with SHPS.